In 2023, Hungary led with 2% of total sales, followed by Austria at 1.3%. Italy and Slovenia each accounted for 0.7%. Belgium, Norway, and Finland had smaller shares, with 0.4%, 0.3%, and 0.3%, respectively. Noticeable changes from the previous year include a 1.03% increase in Hungary and a significant -7.79% drop in Chile. Other countries, such as Iceland and South Korea, showed no year-over-year variation.
Future Trends to Watch
Future trends will likely be influenced by aging populations in Europe and increased healthcare access in emerging markets. Monitoring economic stability and healthcare policies in countries like Hungary and Austria will be key to predicting future sales shifts. Watch for technological advancements and innovations in antihypertensive therapies that could reshape market dynamics.
Top countries in Antihypertensive Medicine Sales by Country
# | 10 Countries | Percent of Total Sales | Last Year | YoY | 5-years CAGR | |
---|---|---|---|---|---|---|
1 | 1 Hungary | 2 | 2023 | +5.26% | +1.03% | View data |
2 | 2 Austria | 1.3 | 2023 | 0% | -1.47% | View data |
3 | 3 Italy | 0.7 | 2023 | 0% | -2.64% | View data |
4 | 4 Slovenia | 0.7 | 2023 | 0% | 0% | View data |
5 | 5 Belgium | 0.4 | 2023 | 0% | 0% | View data |
6 | 6 Norway | 0.3 | 2023 | 0% | -5.59% | View data |
7 | 7 Finland | 0.3 | 2023 | 0% | 0% | View data |
8 | 8 Estonia | 0.3 | 2023 | 0% | 0% | View data |
9 | 9 Chile | 0.2 | 2023 | 0% | -7.79% | View data |
10 | 10 Iceland | 0.2 | 2023 | 0% | 0% | View data |